Daraxonrasib

Daraxonrasib is an investigational new drug being evaluated by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcinoma containing KRAS G12X mutations. It has received a breakthrough therapy designation from the U.S. Food and Drug Administration.
Daraxonrasib is an orally active, multi-selective RAS inhibitor that uses a novel tri-complex mechanism to target the active, GTP-bound form of RAS proteins, including mutant and wild-type types. Unlike conventional RAS inhibitors, it first binds to the chaperone-like protein cyclophilin A to form a complex, which then attaches to active RAS. This interaction blocks downstream effector binding and inhibits oncogenic signaling.
As of 2025, Daraxonrasib clinical trial is in phase 3 to assess efficacy compared to current standard-of-care chemotherapy.